Brief: Roche’s fenebrutinib significantly reduced relapses in RMS
22/04/2026 06:22
April 22 (Reuters) - RocheROPC.S: Fenebrutinib, an investigational non-covalent bruton’s tyrosine kinase (btk) inhibitor, reduced the annualised relapse rate (arr) by 51.1% (p<0.001) in FENhance 1 58.5% (p<0.0001) reduction in FENhance 2 compared with teriflunomide in patients with relapsing multiple sclerosis (RMS) over 96 weeks Further company coverage: [ROPC.S] (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Roche Holding AG
See all newsTable: Swiss trade surplus at CHF 6.11 bln in May
Brief: Roche - FDA Accepts Supplemental Biologics License Application For Lunsumio And Polivy Combination
Swiss stocks - Factors to watch on June 18
FDA approves first generic version of Roche's flu drug
Brief: FDA Approves First Single-Dose Generic Treatment For Influenza